The Pharmaceutical Market : Egypt

By Author: Bharat Book Bureau
Total Articles: 1486
Comment this article

On 25th November 2011, Kamal Ahmad el-Ganzouri was appointed head of the Egyptian Salvation Government. According to the Economist Intelligence Unit (EIU), the Supreme Council of the Armed Forces (SCAF) held a lower house parliamentary election between 28th November 2011 and 3rd January 2012. During this third round, more than 14 million people were eligible to vote on the 150 seats in nine governorates. Entering this final round, the Muslim Brotherhood had registered more than 40% of the vote, with its main rival, the Al Nour party, gaining more than 20%. In final results, made public on 21st January 2012, the Brotherhood held a majority of 47% and the Nour Party had 24.3% of seats. Final results are expected in the week commencing 9th January 2012. Elections for the less-powerful upper house of parliament, the Shura Council, began on 29th January 2012, while presidential elections are scheduled for June 2012. As a result, the SCAF is expected to control power until a new president is elected. The EIU adds that the SCAF envisages that the presidential election will take place after the referendum on the new constitution, which ...
... would mean that Egypt would continue to be under military control for most of 2012 and perhaps part of 2013. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-egypt.html

Providing the political situation stabilises and the economy continues to perform well, the Egyptian pharmaceutical market at retail prices is expected to rise by a double-digit CAGR in US dollar terms between 2011 and 2016. Espicom estimates that the market increased by nearly five times between 1995 and 2010. Nevertheless, per capita consumption is still low. In spite of recent production problems, production is expected to rise as the healthcare system continues its transition towards modernisation. The new pharmaceutical pricing system, if it was fully implemented, would increase the price of new branded and generic pharmaceuticals. Considering opportunities beyond BRIC pharmaceutical markets, Egypt is becoming a very attractive market for multinational pharmaceutical companies focused on emerging markets.

The Egyptian pharmaceutical industry has enjoyed a period of considerable development in recent years. There is a strong domestic production sector and, while the majority is destined for the domestic market and imports play an important role, Egypt has emerged as a leading exporter of pharmaceuticals to Arab, Asian and Eastern European markets. Public production, represented by the state-owned holding company HOLDIPHARMA, accounts for around one-tenth of sales by value and nearly two-tenths by volume. There are a number of leading local private producers, some of them involved in biotechnology, which are strengthening their capabilities; Minapharm Pharmaceuticals, for example, acquired 95.0% of the share capital of the German ProBioGen in June 2010. Some leading multinational producers also manufacture in Egypt, including AstraZen.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH

Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles
EXECUTIVE SUMMARY. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections .3
MACROENVIRONMENT .... 4
POLITICAL4
ECONOMIC ...5
Projections ...5
LEGAL..6
Intellectual Property Rights6
DEMOGRAPHIC 6
Projections ...6
Demographic Indicators.7
EPIDEMIOLOGY.. 8
DISEASE BURDEN..8
DISEASE PREVALENCE....8
Communicable Diseases.8
Non-Communicable Diseases ..8
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS .... 9
ORGANISATION9
Government Sector (Ministry of Health)9
Public Sector9
Private Sector....9
Healthcare Reforms..10
EXPENDITURE.11
Projections .11
Health Insurance .12
Health Insurance Bill 12
Health Insurance Systems Development Project. 12
Health Insurance Beneficiaries.. 12
INFRASTRUCTURE....13
SERVICES14
Hospital Inpatient Services ....14
WORKFORCE...14
Projections .14
REGULATORY AFFAIRS ... 15
PHARMACEUTICAL REGISTRATION15
NATIONAL DRUGS POLICY16
Essential Drugs List ..16
PRICING & REIMBURSEMENT... 17
PRICING..17
New Drug Pricing Decree...17
DISTRIBUTION CHANNELS.. 18
WHOLESALING ....18
Public Wholesalers ...18
Egydrug.. 18
El-Gomhouria . 19
Private Wholesalers .19
Multipharma .. 19
PharmaOverseas. 19
UCP 19
RETAILING.. 20
Pharmacy Chains .20
El-Ezaby Pharmacy Chain ...20
Misr Pharmacies..20
Seif Pharmacies....20
MARKET ANALYSIS 21
SIZE....21
Projections .21
Historical Market Figures...23
Current Structure.24
PRODUCT DEVELOPMENT.... 25
MANUFACTURING....26
TRADE ... 28
Exports ..28
Imports..30
Balance of Trade ..34
COMPETITION... 35
TRADE ASSOCIATIONS .35
AUPAM....35
FEI .35
TRADE FAIR 35
COMPANY INTELLIGENCE.35
Public Sector Producers 35
ADCO..37
Alexandria ..38
CID.38
El-Nasr....39
Kahira 40
Memphis 41
Misr .... 41
Nile42
Local Private Producers 43
Arab Company for Drug Industries and Medical Appliances (ACDIMA) ..43
For more information kindly visit :
The Pharmaceutical Market : Egypt

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/